Zydus Lifesciences has announced a partnership with CVS Caremark, a CVS Health company, to include its diabetes treatments—Zituvio, Zituvimet, and Zituvimet XR—in the CVS Caremark template formulary. This collaboration, effective from January 1, 2025, aims to improve access to affordable and high-quality diabetes medications in the U.S. The Zituvio range comprises:
As per the press statement, these medications are designed to enhance glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. They feature sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride, a biguanide. All three products have received USFDA approval through the 505(b)(2) pathway, signifying their efficacy and safety.
Punit Patel, President & CEO of Zydus Pharmaceuticals USA Inc., commented on the agreement, saying, “We are proud to partner with CVS Caremark, a leader in patient-centric healthcare solutions. This collaboration reinforces our commitment to improving access to high-quality medications while reducing healthcare costs.”
The demand for diabetes medications in the U.S. has surged, reflecting the growing prevalence of metabolic and lifestyle-related conditions. According to IQVIA (MAT August 2023), the U.S. market for DPP-4 inhibitors and their combinations is valued at USD 10 billion.
This partnership highlights Zydus’ focus on strengthening its presence in the U.S. market with differentiated and high-value products. The company continues to invest in innovation, particularly within its 505(b)(2) portfolio, to meet global healthcare needs.
_20250108163943_original_image_21.webp)
_20250108121431_original_image_5.webp)